News & Updates

Dupilumab, barzolvolimab, and remibrutinib appear to help reduce disease activity in patients with chronic spontaneous urticaria, according to the results of three studies presented at AAAAI 2023.

Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway appears to be causally associated with a lower risk of psoriasis, regardless of the concentration levels of circulating low-density lipoprotein (LDL), according a two-sample Mendelian randomization study.

A diagnosis of discoid lupus erythematosus (DLE) at age 25 years or below, phototype V to VI, and antinuclear antibody titers of ≥1:320 are significantly associated with the development of severe systemic lupus erythematosus (SLE), according to a study.

For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.

Clinicians must be aware of the likelihood of infection with herpes simplex virus (HSV) in the presence of fissures, haemorrhagic crusts, linear erosions, erosions with angulated margins, and increased erythrocyte sedimentation rate among patients with pemphigus vulgaris, suggests a study.

The incidence of psoriasis may be decreased by maintaining a normal weight and by putting a stop to the use of tobacco and cigarettes, a recent study has shown. In addition, addressing the inequality in education may help lower the cases of this condition.

Outpatient oritavancin therapy appears to be more effective than inpatient standard-of-care (SoC) in reducing 30-day hospital readmissions or admissions among individuals with acute uncomplicated cellulitis, a recent study has shown.

Treatment with dupilumab helps improve the signs and symptoms of erythrodermic atopic dermatitis, with the improvements occurring as early as the first week and being sustained over time, according to a study. The drug has an acceptable safety profile.